Total revenue from continuing operations increased 8%; constant currency organic revenue grew 6%As reported EPS from continuing operations increased to $1.41; adjusted EPS increased to $2.03Fiscal 2025 outlook reiterated DUBLIN, IRELAND , Aug. 06, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2025 first quarter ended June 30, 2024. Total revenue from continuing operations for the first quarter of fiscal 2025 increased 8% to $1.3 ...

Total revenue from continuing operations increased 8%; constant currency organic revenue grew 6%As reported EPS from continuing operations increased to $1.41; adjusted EPS increased to $2.03Fiscal 2025 outlook reiterated DUBLIN, IRELAND , Aug. 06, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 first quarter ended June 30, 2024. Total revenue from continuing operations for the first quarter of fiscal 2025 increased 8% to $1.3 ...

DUBLIN, IRELAND, July 31, 2024 (GLOBE NEWSWIRE) --  STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. This represents a $0.05 increase in the dividend and the Company's 19th consecutive year of dividend growth. The dividend is payable on September 20, 2024, to shareholders of record at the close of business on September 5, 2024.   Additional information about the U.S. tax treatment of dividends, including requi ...

DUBLIN, IRELAND, July 31, 2024 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. This represents a $0.05 increase in the dividend and the Company’s 19th consecutive year of dividend growth. The dividend is payable on September 20, 2024, to shareholders of record at the close of business on September 5, 2024.   Additional information about the U.S. tax treatment of dividends, including requ ...

DUBLIN, IRELAND, July 23, 2024 (GLOBE NEWSWIRE) --  STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 first quarter financial results at 9:00 a.m. ET on August 7, 2024. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.   A press release detailing financial results will be ...

DUBLIN, IRELAND, July 23, 2024 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2025 first quarter financial results at 9:00 a.m. ET on August 7, 2024. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.   A press release detailing financial results will be ...

STERIS plc (STE) is expected to release first-quarter fiscal 2025 results on Aug 6.Earnings Surprise HistorySTE has a strong earnings surprise history. It beat on earnings in three of the trailing four quarters and missed the same once, the average surprise being 2.21%.In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.41, in line with the Zacks Consensus Estimate.Q1 EstimatesThe Zacks Consensus Estimate for STERIS’ first-quarter fiscal 2025 revenues is pegged at $1.26 ...

STERIS' (STE) strong rebound of procedure volumes in the United States is leading to solid growth in the Healthcare business. The company carries a Zacks Rank #2 (Buy) at present.STERIS’ Healthcare segment is gaining from the successful market adoption of its comprehensive offerings, including infection prevention consumables and capital equipment. Further, its services to maintain these equipments, repair reusable procedural instruments and outsource instrument reprocessing services are gaining traction. O ...

STERIS plc (STE) stands to benefit from the growing pharmaceutical and healthcare industries in the upcoming quarters, supported by favorable dynamics as well as strategic additions. The Healthcare arm is gaining from the positive volume environment in the United States and capturing market share. Also, the strong rebound prospects of Applied Sterilization Technologies (“AST”) are encouraging.Meanwhile, the impacts of macroeconomic challenges and increasing consolidation in the industry pose a worry for the ...

STERIS’ (STE) strong rebound of procedure volumes in the United States is leading to solid growth in the Healthcare business. Yet, a fiercely competitive market offsets the positive. The stock carries a Zacks Rank #3 (Hold) at present. STERIS’ Healthcare segment is gaining from the successful market adoption of its comprehensive offerings, including infection prevention consumables and capital equipment. Further, its services to maintain that equipment, repair reusable procedural instruments and outsource i ...